Blph stock quarterly report
Apr 03, 2020 · Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, closed its previously announced registered direct offering of 1,275,000 shares of its common stock at a purchase price of $12.00 per share for total gross proceeds of $15.3 million, before deducting placement agent fees and offering expenses.